Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion. [PDF]
J Cancer Res Clin Oncol, 2022 Xie X +5 more
europepmc +1 more source
Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study [PDF]
, 2018 et al, +2 more
core +1 more source
Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib. [PDF]
Neuro Oncol, 2022 Papusha L +13 more
europepmc +1 more source
Rare dual MYH9-ROS1 fusion variants in a patient with lung adenocarcinoma: A case report. [PDF]
Medicine (Baltimore)Luo T +5 more
europepmc +1 more source
Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. [PDF]
, 2017 Jalal, Shadia I., Mamdani, Hirva
core +1 more source
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer [PDF]
JCO Precision Oncology, 2018 Pishvaian, Michael J. +5 more
openaire +3 more sources
Acquired ROS1 fusion and iruplinalkib response in advanced NSCLC after multiple lines of systematic therapy: a case report. [PDF]
Front OncolLiu J +7 more
europepmc +1 more source
Entrectinib-Induced Brugada Syndrome Leading to Ventricular Tachycardia in A Patient with ROS1 Fusion-Positive Lung Adenocarcinoma. [PDF]
Eur J Case Rep Intern MedIshiguro N +6 more
europepmc +1 more source
Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report. [PDF]
Thorac Cancer, 2021 Wu CH, Su PL, Hsu CW, Chu CY, Lin CC.
europepmc +1 more source
Detection of ROS1 Rearrangement Using Immunohistochemistry: Correlation With ROS1 Fusion Analysis by Fluorescence In Situ Hybridization [PDF]
American Journal of Clinical Pathology, 2018 Brittany Coffman +3 more
openaire +1 more source